Intellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPR gene editing therapy for the treatment of ...

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...

Intellia Therapeutics Inc (NTLA) stock saw a modest uptick, ending the day at $9.5 which represents a slight increase of $0.08 or 0.85% from the prior close of $9.42. The stock opened at $9.48 and ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

Technical analysis for Intellia Therapeutics Inc. NTLA including support levels resistance levels and stop losses for NTLA ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

Shares of Intellia Therapeutics, Inc. NTLA were down in pre-market trading on Jan. 10 after the company announced a strategic reorganization to prioritize its portfolio of late-stage pipeline ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia ...